LONDON - Britain's medicine regulator has identified a possible side-effect from COVID-19 vaccine developed by Oxford University and AstraZeneca involving rare brain blood clotting, chief executive June Raine said on Wednesday.
She added that its benefits outweighed the risks for the vast majority.
(Reporting by Alistair Smout; editing by James Davey)
Regulated by IMPRESS:
The Independent Monitor
for the Press CIC
IMPRESS, 16-18 New Bridge Street,
London, EC4V 6AG
T: 020 3325 4288
E: complaints@impress.press
W: impress.press